Caspase Activation and Changes in Bcl-2 Family Member Protein Expression Associated with E2F-1-mediated Apoptosis in Human Esophageal Cancer Cells
Overview
Authors
Affiliations
The prognosis for patients with esophageal cancer remains poor, prompting the search for new treatment strategies. Overexpression of E2F-1 has been shown to induce apoptosis in several cancer cell types. In the present study, the effect of adenovirus-mediated E2F-1 overexpression on human esophageal cancer cell lines Yes-4 and Yes-6 was evaluated. Cells were treated by mock infection, infection with an adenoviral vector expressing beta-galactosidase (Ad5CMV-LacZ), or E2F-1 (Ad5CMVE2F-1). Western blot analysis confirmed marked overexpression of E2F-1 in Ad5CMVE2F-1-infected cells. Overexpression of E2F-1 resulted in marked growth inhibition and rapid loss of cell viability due to apoptosis, although Yes-6 cells were somewhat more resistant to E2F-1-mediated growth inhibition than Yes-4 cells. Cell cycle analysis revealed that overexpression of E2F-1 led to G2 arrest, followed by apoptotic cell death. p53 expression remained undetectable in both cell lines after E2F-1 overexpression. The apoptosis inhibitor proteins of the Bcl-2 gene family, Bcl-2, Mcl-1, and BcI-XL, decreased at 48 h after infection in Yes-4 cells, but remained unchanged in Yes-6 cells. Levels of retinoblastoma gene product (pRb) declined at 48 h after E2F-1 infection in Yes-4 cells, at which apoptosis predominated, whereas pRb expression remained constant in Yes-6 cells. Expression of p14ARF did not change after E2F-1 infection in either cell line. Involvement of caspase 3 and caspase 6 in E2F-1-mediated apoptosis was demonstrated by cleavage of caspase 3/CPP32 and poly-ADP-ribose polymerase, as well as fragmentation of the caspase 6 substrate, lamin B. These results indicate that the sensitivity of esophageal cancer cells to E2F-1-mediated apoptosis may be related to differential expression of Bcl-2 family member proteins and suggest that the adenovirus-mediated E2F-1 gene therapy may be a promising treatment strategy for the treatment of this disease.
Jiang W, Tian J, Guo Y, Qiu L, Luo X, Huang Y Cancer Cell Int. 2024; 24(1):119.
PMID: 38553712 PMC: 10981364. DOI: 10.1186/s12935-024-03286-5.
Cheng Z, Yi Y, Xie S, Yu H, Peng H, Zhang G Oncotarget. 2018; 8(63):106753-106763.
PMID: 29290986 PMC: 5739771. DOI: 10.18632/oncotarget.22053.
ABT-263 induces G/G-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro.
Lin Q, Que F, Gu C, Zhong D, Zhou D, Kong Y Acta Pharmacol Sin. 2017; 38(12):1632-1641.
PMID: 28713162 PMC: 5719159. DOI: 10.1038/aps.2017.78.
Zou M, Duan Y, Wang P, Gao R, Chen X, Ou Y Sci Rep. 2016; 6:27331.
PMID: 27251589 PMC: 4890319. DOI: 10.1038/srep27331.
E2F-1 overexpression inhibits human gastric cancer MGC-803 cell growth in vivo.
Wei W, Yan L, Wang X, Li L, Cao W, Zhang X World J Gastroenterol. 2015; 21(2):491-501.
PMID: 25593464 PMC: 4292280. DOI: 10.3748/wjg.v21.i2.491.